Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Second Pharmaceutical Signs Collaborative Agreements With Foreign Firms

This article was originally published in PharmAsia News

Executive Summary

Beijing Second Pharmaceutical, a subsidiary of Beijing Pharmaceutical Group, has signed a series of collaborative agreements to speed up its globalization strategy. These include: a new partnership with U.S. Frontage Laboratories to expand cooperation of generic drug R&D; a three-party agreement with Poland-based Adamed and Beijing CoSci Med-Tech on drug R&D, import and export registration, outsourced manufacturing and marketing, as well as cGMP authentication application; and a collaboration with an American pharmaceutical distributor to prepare for Beijing Second's product launch in the U.S. With the agreements signed and ready to be executed, Beijing Second can look forward to launching its pharmaceutical formulations internationally. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel